Here are five things to know.
- Symjepi is a single-dose prefilled syringe of epinephrine intended to treat emergency allergic reactions, including anaphylaxis.
- The injection will directly compete with Mylan’s EpiPen, which holds a majority of the epinihprine injection market.
- Adamis has not disclosed an official price for Symjepi. The drugmaker hopes to sell a two-pack of Symjepi for cheaper than Mylan’s generic EpiPens, which cost $300 for a pack of two, reports CBS News.
- The drugmaker plans to launch the product in the second half of 2017.
- Adamis will also submit a new drug application to the FDA for a lower-dose version of Symjepi, which will compete with Mylan’s EpiPen Jr.
More articles on supply chain:
Nevada governor signs drug price transparency legislation: 5 things to know
Hospira recalls several injectables over sterility concerns
Trump administration readies executive order addressing drug prices
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
